1. Home
  2. HUMAW vs IMNM Comparison

HUMAW vs IMNM Comparison

Compare HUMAW & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Humacyte Inc. Warrant

HUMAW

Humacyte Inc. Warrant

N/A

Current Price

$0.09

Market Cap

0.0

Sector

Health Care

ML Signal

N/A

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$20.62

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUMAW
IMNM
Founded
2004
2006
Country
United States
United States
Employees
220
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medicinal Chemicals and Botanical Products
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
1.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
HUMAW
IMNM
Price
$0.09
$20.62
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$31.44
AVG Volume (30 Days)
14.2K
3.0M
Earning Date
03-21-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$9,679,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$11.53
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.18
$5.15
52 Week High
$1.34
$25.30

Technical Indicators

Market Signals
Indicator
HUMAW
IMNM
Relative Strength Index (RSI) 38.04 52.50
Support Level $0.09 $21.00
Resistance Level $0.12 $22.57
Average True Range (ATR) 0.03 1.40
MACD 0.00 -0.18
Stochastic Oscillator 8.62 29.74

Price Performance

Historical Comparison
HUMAW
IMNM

About HUMAW Humacyte Inc. Warrant

Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Company's pipeline includes Vascular Trauma, PAD, Dailysis, Acellular Tissue Engineered Vessels, Organ Systems, Advanced Tissue Constructs.

About IMNM Immunome Inc.

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.

Share on Social Networks: